Rapidly Progressive Glomerulonephritis
By:
Dario Roccatello University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases, Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases, Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Città di Torino and University of Torino, Turin, Italy

Search for other papers by Dario Roccatello in
Current site
Google Scholar
PubMed Close
and
Roberta Fenoglio University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases, Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases, Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Città di Torino and University of Torino, Turin, Italy

Search for other papers by Roberta Fenoglio in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 23: Issue 3
Published Online:
Aug 2024
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2024 by the American Society of Nephrology 2024
Page Count:
13
Article Category:
Research Article
Print Publication Date:
01 Aug 2024
Published Online:
Aug 2024
  • 1.

    Singh A, Everest S, Nguyen L, Kasari M: ANCA-associated vasculitis in a patient presenting with rapid progressive glomerulonephritis. Cureus 13: e20227, 2021 10.7759/cureus.20227 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Naik RH, Shawar SH: Rapidly Progressive Glomerulonephritis, Stat Pearls. Treasure Island (FL): StatPearls Publishing, 2021. Available at https://www.statpearls.com/point-of-care/22288. Accessed May 6, 2024.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Berti A, Cornec-Le Gall E, Cornec D, Casal Moura M, Matteson EL, Crowson CS, et al.: Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant 34: 1508–1517, 2019 10.1093/ndt/gfy250 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Parmar MS, Bashir K: Crescentric Glomerulonephritis, StatPearls. Treasure Island (FL) StatPearls Publishing, 2021. Available at https://www.statpearls.com/point-of-care/22279. Accessed May 6, 2024.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    DeVrieze BW, Hurley JA: Goodpasture Syndrome, StatPearls. Treasure Island (FL): StatPearls Publishing, 2024. Available at https://www.statpearls.com/point-of-care/22371. Accessed May 6, 2024.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Henique C, Bollee G, Lenoir O, Dhaun N, Camus M, Chipont A, et al.: Nuclear factor erythroid 2-related factor 2 drives podocyte-specific expression of peroxisome proliferator-activated receptor γ essential for resistance to crescentic GN. J Am Soc Nephrol 27: 172–188, 2016 10.1681/ASN.2014111080 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Wang Z, Chen X, Zhang D, Cao Y, Zhang L, Tang W: PYCARD gene plays a key role in rapidly progressive glomerulonephritis: results of a weighted gene co-expression network analysis. Am J Nephrol 48: 193–204, 2018 10.1159/000492725 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Sowa M, Trezzi B, Hiemann R, Schierack P, Grossmann K, Scholz J, et al.: Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis. Medicine (Baltimore) 95: e5225, 2016 10.1097/MD.0000000000005225 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Fenoglio R, Sciascia S, Baldovino S, Roccatello D: Acute kidney injury associated with glomerular diseases. Curr Opin Crit Care 25: 573–579, 2019 10.1097/MCC.0000000000000675 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Anguiano L, Kain R, Anders HJ: The glomerular crescent: Triggers, evolution, resolution, and implications for therapy. Curr Opin Nephrol Hypertens 29: 302–309, 2020 10.1097/MNH.0000000000000596 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, et al.: Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol 20: 322–341, 2016 10.1007/s10157-015-1218-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Reggiani F, L’Imperio V, Calatroni M, Pagni F, Sinico RA: Goodpasture syndrome and anti-glomerular basement membrane disease. Clin Exp Rheumatol 41: 964–974, 2023 10.55563/clinexprheumatol/tep3k5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Gulati K, McAdoo SP: Anti-glomerular basement membrane disease. Rheum Dis Clin North Am 44: 651–673, 2018 10.1016/j.rdc.2018.06.011 PubMed

  • 14.

    Segelmark M, Hellmark T: Anti-glomerular basement membrane disease: An update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant 34: 1826–1832, 2019 10.1093/ndt/gfy327 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Marques C, Plaisier E, Cacoub P, Cadranel J, Saadoun D: Review on anti-glomerular basement membrane disease or Goodpasture’s syndrome. Rev Med Interne 41: 14–20, 2020 10.1016/j.revmed.2019.10.338 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Shen CR, Jia XY, Cui Z, Yu XJ, Zhao MH: Clinical-pathological features and outcome of atypical anti-glomerular basement membrane disease in a large single cohort. Front Immunol 11: 2035, 2020 10.3389/fimmu.2020.02035 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Akhtar M, Taha NM, Asim M: Anti-glomerular basement membrane disease: What have we learned? Adv Anat Pathol 28: 59–65, 2021 10.1097/PAP.0000000000000280 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Marques C, Carvelli J, Biard L, Faguer S, Provôt F, Matignon M, et al.: Prognostic factors in anti-glomerular basement membrane disease: A multicenter study of 119 patients. Front Immunol 10: 1665, 2019 10.3389/fimmu.2019.01665 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Elshirbeny M, Alkadi MM, Mujeeb I, Fituri O: Atypical anti-glomerular basement membrane disease with diffuse crescentic membranoproliferative glomerulonephritis: Case report and review of literature. Qatar Med J 2020: 16, 2020 10.5339/qmj.2020.16 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Kiani R, Shahid M: Anti-glomerular basement membrane (anti-Gbm) disease - Effect of early diagnosis and treatment on prognosis. S D Med 73: 208–211, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100: 753–779, 2021 10.1016/j.kint.2021.05 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Elia F, Pagnozzi F, Laface B, Aprà F, Roccatello D: A victim of the Occam’s razor. Intern Emerg Med 8: 767–768, 2013 10.1007/s11739-013-0954-6 PubMed

  • 23.

    Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, et al.: Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: An open-label phase 2a study. J Am Soc Nephrol 33: 829–838, 2022 10.1681/ASN.2021111460 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Zahir Z, Wani AS, Prasad N, Jain M: Clinicopathological characteristics and predictors of poor outcome in anti-glomerular basement membrane disease - A fifteen year single center experience. Ren Fail 43: 79–89, 2021 10.1080/0886022X.2020.1854301 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Aibara N, Ohyama K: Revisiting immune complexes: Key to understanding immune-related diseases. Adv Clin Chem 96: 1–17, 2020 10.1016/bs.acc.2019.11.00 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Nakazawa D, Masuda S, Tomaru U, Ishizu A: Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15: 91–101, 2019 10.1038/s41584-018-0145-y PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Haas M, Eustace JA: Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases. Kidney Int 65: 2145–2152, 2004 10.1111/j.1523-1755.2004.00632.x PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Kronbichler A, Lee KH, Denicolò S, Choi D, Lee H, Ahn D, et al.: Immunopathogenesis of ANCA-associated vasculitis. Int J Mol Sci 21: 7319, 2020 10.3390/ijms21197319 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Brilland B, Garnier AS, Chevailler A, Jeannin P, Subra JF, Augusto JF: Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmun Rev 19: 102424, 2020 10.1016/j.autrev.2019.102424 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170: 52–64, 2007 10.2353/ajpath.2007.060573 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Deshayes S, Aouba A, Khoy K, Mariotte D, Lobbedez T, Martin Silva N: Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One 13: e0195680, 2018 10.1371/journal.pone.0195680 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Lin W, Shen C, Zhong Y, Ooi JD, Eggenhuizen P, Zhou YO, et al.: Glomerular immune deposition in MPO-ANCA associated glomerulonephritis is associated with poor renal survival. Front Immunol 12: 625672, 2021 10.3389/fimmu.2021.625672 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Kallenberg CG, Heeringa P: Complement is crucial in the pathogenesis of ANCA-associated vasculitis. Kidney Int 83: 16–18, 2013 10.1038/ki.2012.371 PubMed

  • 34.

    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, RAVE-ITN Research Group, et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, European Vasculitis Study Group, et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220, 2010 10.1056/NEJMoa0909169 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Walsh M, Merkel PA, Peh PC, Szpirt WM, Puéchal X, Fujimoto S, PEXIVAS Investigators, et al.: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622–631, 2020 10.1056/NEJMoa1803537 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Casal Moura M, Irazabal MV, Eirin A, Zand L, Sethi S, Borah BJ, et al.: Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol 31: 2688–2704, 2020 10.1681/ASN.2019111197 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Walsh M, Collister D, Zeng L, Merkel PA, Pusey CD, Guyatt G, Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis BMJ Rapid Recommendations Group, et al.: The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis. BMJ 376: e064604, 2022 10.1136/bmj-2021-064604 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Casal Moura M, Crowson CS, Specks U, Warrington KJ, Zand L, Sethi S, et al.: PLEX in AAV-GN: Insights from the meta-analysis results and impact on remission induction treatment recommendations. Clin Kidney J 16: 432–436, 2022 10.1093/ckj/sfac221 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group: Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384: 599–609, 2021 10.1056/NEJMoa2023386 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al.: EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83: 30–47, 2024 10.1136/ard-2022-223764 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al.: 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73: 1366–1383, 2021 https://doi.org/10.1002/art.41773 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Roccatello D, Sciascia S, Murgia S, Quattrocchio G, Ferro M, De Simone E, et al.: Treating patients with ANCA-associated vasculitis and very severe renal injury with an intensified B cell depletion therapy: Comparison with a control cohort receiving a conventional therapy. Front Immunol 13: 777134, 2022 10.3389/fimmu.2022.777134 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, French Vasculitis Study Group, et al.: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371: 1771–1780, 2014 10.1056/NEJMoa1404231 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, French Vasculitis Study Group, et al.: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77: 1143–1149, 2018 10.1136/annrheumdis-2017-212878 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, French Vasculitis Study Group, et al.: Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 173: 179–187, 2020 10.7326/M19-3827 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, et al.: The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. Oncotarget 8: 52072–52077, 2017 10.18632/oncotarget.18120 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Roccatello D: “How I treat” autoimmune diseases: State of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis. Autoimmun Rev 16: 995–998, 2017 10.1016/j.autrev.2017.07.015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Roccatello D, Padoan R, Sciascia S, Iorio L, Ríogh E, Little MA: Might maintenance therapy be discontinued once clinical remission is achieved in ANCA-associated vasculitis? Autoimmun Rev 23: 103438, 2023 10.1016/j.autrev.2023.103438 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Parikh SV, Almaani S, Brodsky S, Rovin BH: Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis 76: 265–281, 2020 10.1053/j.ajkd.2019.10.017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15: 241–250, 2004 10.1097/01.asn.0000108969.21691.5d PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Calle-Botero E, Abril A: Lupus vasculitis. Curr Rheumatol Rep 22: 71, 2020 10.1007/s11926-020-00937-0 PubMed

  • 53.

    Rijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K, et al.: Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol 12: 734–743, 2017 10.2215/CJN.10601016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Komolafe OO: Rapidly progressive glomerulonephritis: A wild card manifestation of lupus nephritis. Saudi J Kidney Dis Transpl 29: 443–451, 2018 10.4103/1319-2442.229293 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Cai F, Han F, Wang H, Han H, Le J, Lan L, et al.: The crescentic implication of renal outcomes in proliferative lupus nephritis. J Rheumatol 45: 513–520, 2018 10.3899/jrheum.170553 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Oliveira C, Mariz H, Fernandes G, Costa D, Cavalcante MA, Valente L: Lupus nephritis class IV-global is associated with a higher risk of end-stage renal disease than class IV-segmental. Nephron 144: 118–125, 2020 10.1159/000505404 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Ayoub I, Nachman PH: Advances in ANCA-associated vasculitis and lupus nephritis. Nat Rev Nephrol 17: 89–90, 2021 10.1038/s41581-020-00388-x PubMed

  • 58.

    Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Balk EM, et al.: Executive summary of the KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int 105: 31–34, 2024 10.1016/j.kint.2023.09.001 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al.: Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [published erratum appears in Lancet 397: 2048 2021]. Lancet 397: 2070–2080, 2021 10.1016/S0140-6736(21)00578-X PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, et al.: EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63: 525–529, 2004 10.1136/ard.2002.003574 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al.: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78: 736–745, 2019 10.1136/annrheumdis-2019-215089 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al.: Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med 162: 18–26, 2015 10.7326/M14-1030 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, LUNAR Investigator Group, et al.: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215–1226, 2012 10.1002/art.34359 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Sans-Pola C, Danés I, Bosch JÀ, Marrero-Álvarez P, Cortés J, Agustí A: Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: A retrospective study and literature review. Front Med (Lausanne) 10: 1159794, 2023 10.3389/fmed.2023.1159794 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, et al.: Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 26: 3987–3992, 2011 Dec PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Roccatello D, Sciascia S, Naretto C, Alpa M, Fenoglio R, Ferro M, et al.: A Proscpective Study on Long-Term Clinical Outcomes of patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. Kidney Int Rep 6: 1081–1087, 2021 10.1016/j.ekir.2021.01.027 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, et al.: Cryoglobulinaemia. Nat Rev Dis Primers 4: 11, 2018 10.1038/s41572-018-0009-4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Rossi D, Sciascia S, Fenoglio R, Ferro M, Baldovino S, Kamgaing J, et al.: Cryoglobulinemic glomerulonephritis: Clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. Minerva Med 112: 162–174, 2021 10.23736/S0026-4806.20.07076-7 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Roccatello D, Fenoglio R, Sciascia S: The dilemma of treating hepatitis C virus-associated cryoglobulinemia. Curr Opin Rheumatol 31: 499–504, 2019 10.1097/BOR.0000000000000624 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al.: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19: 3054–3061, 2004 10.1093/ndt/gfh469 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Kaartinen K, Safa A, Kotha S, Ratti G, Meri S: Complement dysregulation in glomerulonephritis. Semin Immunol 45: 101331, 2019 10.1016/j.smim.2019.101331 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Sethi S, Fervenza FC: Membranoproliferative glomerulonephritis– A new look at an old entity. N Engl J Med 366: 1119–1131, 2012 PubMed

  • 73.

    Madden B, Singh RD, Haas M, Palma LMP, Sharma A, Vargas MJ, et al.: Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy. Kidney Int 105: 1077–1087, 2024 May PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Spanish Group for the Study of Glomerular Diseases (GLOSEN), et al.: Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88: 1153–1160, 2015 10.1038/ki.2015.227 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, et al.: Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Am J Kidney Dis 72: 84–92, 2018 10.1053/j.ajkd.2017.11.019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Tortajada A, Gutierrez E, Pickering MC, Praga Terente M, Medjeral-Thomas N: The role of complement in IgA nephropathy. Mol Immunol 114: 123–132, 2019 10.1016/j.molimm.2019.07.017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Katafuchi R, Nagae H, Masutani K, Tsuruya K, Mitsuiki K: Comprehensive evaluation of the significance of immunofluorescent findings on clinicopathological features in IgA nephropathy. Clin Exp Nephrol 23: 169–181, 2019 10.1007/s10157-018-1619-6 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Abe T, Kida H, Yoshimura M, Yokoyama H, Koshino Y, Tomosugi N, et al.: Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin Nephrol 25: 37–41, 1986 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Conference Participants, et al.: IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 91: 1014–1021, 2017 10.1016/j.kint.2017.02.003 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Mahanta PJ, Agarawalla B, Sharma M: Clinicopathological features and risk factors analysis of IgA nephropathy associated with acute kidney injury: A single-center retrospective study. Saudi J Kidney Dis Transpl 30: 445–450, 2019 10.4103/1319-2442.256851 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Roccatello D, Ferro M, Coppo R, Giraudo G, Quattrocchio G, Piccoli G: Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant 10: 2054–2059, 1995 PMID: 8643167 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M, et al.: Steroids and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 15: 833–835, 2000 10.1093/ndt/15.6.833 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Selvaskandan H, Cheung CK, Muto M, Barratt J: New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol 23: 577–588, 2019 10.1007/s10157-019-01700-1 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al.: Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Writing Committee of the American Society for Apheresis: The eighth special issue. J Clin Apher 34: 171–354, 2019 10.1002/jca.21705 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Roccatello D, Careddu A, Ferro M, Naretto C, Quattrocchio G, Fenoglio R, et al.: The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patient with histologically active lesions: A comparison with a control cohort receiving conventional therapy. J Nephrol 36: 2223–2231, 2023 10.1007/s40620-023-01636-6 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, et al.: Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol 42: 77–93, 2020 10.1590/2175-8239-JBN-2018-0254 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al.: A randomized controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28: 1306–1313, 2017 10.1681/ASN.2016060640 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Reamy BV, Servey JT, Williams PM: Henoch-Schönlein purpura (IgA vasculitis): Rapid evidence review. Am Fam Physician 102: 229–233, 2020 PubMed

  • 89.

    Du L, Wang P, Liu C, Li S, Yue S, Yang Y: Multisystemic manifestations of IgA vasculitis. Clin Rheumatol 40: 43–52, 2021 10.1007/s10067-020-05166-5 PubMed

  • 90.

    Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, et al.: European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis–The SHARE initiative. Rheumatology (Oxford) 58: 1607–1616, 2019 10.1093/rheumatology/kez041 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Peruzzi L, Coppo R: IgA vasculitis nephritis in children and adults: One or different entities? Pediatr Nephrol 36: 2615–2625, 2020 10.1007/s00467-020-04818-7 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Fenoglio R, Sciascia S, Naretto C, De Simone E, Del Vecchio G, Ferro M, et al.: Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis. Clin Exp Rheumatol 38: 195–200, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Fenoglio R, Naretto C, Basolo B, Quattrocchio G, Ferro M, Mesiano P, et al.: Rituximab therapy for IgA-vasculitis with nephritis: A case series and review of the literature. Immunol Res 65: 186–192, 2017 10.1007/s12026-016-8827-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, et al.: Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol 70: 109–114, 2018 10.1002/art.40339 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Roccatello D, Sciascia S, Di Simone D, Solfietti L, Naretto C, Fenoglio R, et al.: New insights into immune mechanisms underlying response to rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. Autoimmun Rev 15: 529–538, 2016 10.1016/j.autrev.2016.02.014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Nikolopoulou A, Huang-Doran I, McAdoo SP, Griffith ME, Cook HT, Pusey CD: Membranous glomerulonephritis with crescents. Kidney Int Rep 4: 1577–1584, 2019 10.1016/j.ekir.2019.07.021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Hunt EAK, Somers MJG: Infection-related glomerulonephritis. Pediatr Clin North Am 66: 59–72, 2019 10.1016/j.pcl.2018.08.005 PubMed

  • 98.

    Satoskar AA, Parikh SV, Nadasdy T: Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol 16: 32–50, 2020 10.1038/s41581-019-0178-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Nasr SH, Fogo AB: New developments in the diagnosis of fibrillary glomerulonephritis. Kidney Int 96: 581–592, 2019 10.1016/j.kint.2019.03.021 PubMed

  • 100.

    Rosenstock JL, Markowitz GS: Fibrillary glomerulonephritis: An update. Kidney Int Rep 4: 917–922, 2019 10.1016/j.ekir.2019.04.013 PubMed

  • 101.

    Andeen NK, Troxell ML, Riazy M, Avasare RS, Lapasia J, Jefferson JA, et al.: Fibrillary glomerulonephritis: Clinicopathologic features and atypical cases from a multi-institutional cohort. Clin J Am Soc Nephrol 14: 1741–1750, 2019 10.2215/CJN.03870319 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al.: Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol 16: 563–580, 2019 10.1038/s41571-019-0218-0 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al.: Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. J Am Soc Nephrol 31: 435–446, 2020 10.1681/ASN.2019070676 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, et al.: Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience. J Immunother Cancer 7: 2, 2019 10.1186/s40425-018-0478-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, National Comprehensive Cancer Network, et al.: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714–1768, 2018 10.1200/JCO.2017.77.6385 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Fenoglio R, Roccatello D, De Simone E, Del Vecchio G, Ferro M, Quattrocchio G, et al.: The challenging management of cancer: An immunonephrologist’s perspective. Kidney Blood Press Res 46: 114–120, 2021 10.1159/000511256 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 198 198 198
Full Text Views 55 55 55
PDF Downloads 82 82 82